Lantern Pharma Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan Ahead of Schedule

Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven cancer therapy development, has announced the completion of targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan, achieving this milestone ahead of schedule. The trial, which enrolled 10 patients across five sites including the National Cancer Center Japan, focuses on evaluating the efficacy of LP-300 in combination with carboplatin and pemetrexed for never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors.

This achievement underscores Lantern Pharma's strategic expansion into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan, where enrollment continues alongside U.S. sites. The global trial aims to enroll approximately 90 patients, building on promising early U.S. data that showed an 86% clinical benefit rate, including a durable complete response lasting nearly two years. For more details on the trial's progress, visit https://ibn.fm/IcDma.

The completion of enrollment in Japan is a testament to the potential of Lantern Pharma's proprietary RADR(R) platform, which leverages over 100 billion oncology-focused data points and a library of 200+ advanced machine learning algorithms. This platform is at the heart of the company's mission to transform the cost, pace, and timeline of oncology drug discovery and development. With a pipeline that spans multiple cancer indications and an estimated combined annual market potential of over $15 billion USD, Lantern Pharma is poised to make significant contributions to cancer treatment worldwide.